PFG Investments LLC Has $46,000 Stock Position in Altimmune, Inc. $ALT

PFG Investments LLC cut its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 31.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,000 shares of the company’s stock after selling 5,500 shares during the period. PFG Investments LLC’s holdings in Altimmune were worth $46,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ALT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Altimmune by 16.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,392 shares of the company’s stock worth $666,000 after buying an additional 13,126 shares during the period. GAMMA Investing LLC grew its holdings in Altimmune by 214.2% during the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock valued at $34,000 after purchasing an additional 4,598 shares during the period. Bank of New York Mellon Corp grew its holdings in Altimmune by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company’s stock valued at $945,000 after purchasing an additional 2,162 shares during the period. Concurrent Investment Advisors LLC bought a new stake in Altimmune in the first quarter valued at approximately $108,000. Finally, Brown Wealth Management LLC raised its holdings in Altimmune by 100.0% in the first quarter. Brown Wealth Management LLC now owns 100,024 shares of the company’s stock worth $500,000 after purchasing an additional 50,024 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Performance

Shares of ALT opened at $3.93 on Wednesday. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09. Altimmune, Inc. has a 12 month low of $2.90 and a 12 month high of $11.16. The firm has a fifty day simple moving average of $3.70 and a 200 day simple moving average of $4.65. The stock has a market capitalization of $346.86 million, a price-to-earnings ratio of -3.33 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. Research analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALT has been the subject of several research analyst reports. B. Riley decreased their price target on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. UBS Group decreased their target price on Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, August 13th. Wall Street Zen raised Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. The Goldman Sachs Group upgraded shares of Altimmune to a “strong sell” rating in a report on Thursday, July 10th. Finally, JMP Securities cut their price target on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research note on Thursday, July 10th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $17.40.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.